Skip to main content

NovoCure Ltd

NVCR
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001645113

No open-market purchases or sales by NovoCure Ltd insiders were filed in the last 90 days; 218 institutions reported holding it in 13F filings for Q2 2026, worth $1.57B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by NovoCure Ltd insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for NovoCure Ltd, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for NovoCure Ltd
NameTitleLast reported holdingLast filingFilings, past year
Puri Michal NathChief Human Resources Officer203,227Jul 1, 20264
Leonard Frank XChief Executive Officer461,425Jul 1, 20265
Ben Arye BarakGeneral Counsel243,752Jul 1, 20263
Danziger AsafDirector416,742Jul 1, 20261
Hilleman Jeryl LDirector25,471Jun 5, 20262
Leung GabrielDirector101,109Jun 5, 20262
Hung DavidDirector32,075Jun 5, 20262
Vernon W AnthonyDirector209,267Jun 5, 20263
Scannell Timothy JDirector25,898Jun 5, 20262
Madden Martin J.Director30,284Jun 5, 20261
Ocean Allyson JDirector22,934Jun 5, 20262
Stafford KristinDirector22,934Jun 5, 20262
Doyle William FExecutive Chairman328,397Mar 5, 20261
Weinberg UriChf Medical and Innovation Ofr267,190Mar 5, 20262
Cordova AshleyFormer Chief Executive Officer422,570Mar 5, 20262
Leupin NicolasFormer Chief Medical Officer102,979Mar 5, 20262
Paravasthu MukundChief Operating Officer72,832Mar 5, 20264
Brackmann ChristophChief Financial Officer182,842Mar 5, 20262
Groenhuysen Wilhelmus CMChief Operating Officer252,290Aug 6, 20240
Giladi MosheChief Science Officer69,771Feb 29, 20240
Shah PriteshChief Growth Officer124,511Nov 8, 20230
Burke William PatrickChief Human Resources Officer66,447Jul 6, 20230
Benaim ElyChief Medical Officer28,770Jan 10, 20230
Longsworth Todd ChristopherGeneral Counsel62,462Mar 9, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Jun 6, 2024 (view filing)Jun 42 daysLeung GabrielDirectorSSale−964$23.89−$23.0K−1.2%78.2K after
Mar 5, 2024 (view filing)Mar 1-44 daysGroenhuysen Wilhelmus CMChief Operating OfficerSSale−3.32K$16.02−$53.3K−1.3%251.2K after2 lots
Mar 5, 2024 (view filing)Mar 1-44 daysLeonard Frank XEVP, Pres., Novocure OncologySSale−2.52K$16.02−$40.4K−1.5%160.1K after2 lots
Feb 29, 2024 (view filing)Feb 281 dayLeonard Frank XEVP, Pres., Novocure OncologySSale−2.08K$16.14−$33.5K−1.3%162.6K after
Feb 29, 2024 (view filing)Feb 281 dayGroenhuysen Wilhelmus CMChief Operating OfficerSSale−2.30K$16.14−$37.2K−0.9%254.6K after
Nov 8, 2023 (view filing)Nov 71 dayShah PriteshChief Growth OfficerSSale−382$12.65−$4.83K−0.3%124.5K after
Sep 5, 2023 (view filing)Sep 14 daysCordova AshleyChief Financial OfficerSSale−883$21.82−$19.3K−0.9%99.7K after
Sep 5, 2023 (view filing)Sep 14 daysGroenhuysen Wilhelmus CMChief Operating OfficerSSale−294$21.82−$6.42K−0.1%209.8K after
Sep 5, 2023 (view filing)Sep 14 daysShah PriteshChief Growth OfficerSSale−273$21.82−$5.96K−0.2%124.9K after
Aug 4, 2023 (view filing)Aug 22 daysCordova AshleyChief Financial OfficerSSale−1.14K$30.25−$34.6K−1.1%100.5K after
Mar 7, 2023 (view filing)Mar 3-74 daysLeonard Frank XPresident, CNS Cancers USSSale−13.6K$75.55−$1.03M−20.0%54.3K after4 lots
Mar 7, 2023 (view filing)Mar 34 daysShah PriteshChief Growth OfficerSSale−21.4K$76.16−$1.63M−14.6%124.8K after3 lots
Mar 7, 2023 (view filing)Mar 34 daysGroenhuysen Wilhelmus CMChief Operating OfficerSSale−25.6K$76.16−$1.95M−10.9%209.8K after3 lots
Mar 7, 2023 (view filing)Mar 34 daysCordova AshleyChief Financial OfficerSSale−5.50K$76.16−$419.3K−5.2%101.3K after2 lots
Mar 7, 2023 (view filing)Mar 34 daysBurke William PatrickChief Human Resources OfficerSSale−593$76.16−$45.2K−0.9%66.1K after
Mar 6, 2023 (view filing)Mar 24 daysBurke William PatrickChief Human Resources OfficerSSale−281$75.28−$21.2K−0.4%66.7K after
Mar 6, 2023 (view filing)Mar 24 daysShah PriteshChief Growth OfficerSSale−937$75.28−$70.5K−0.9%99.0K after
Mar 6, 2023 (view filing)Mar 24 daysGroenhuysen Wilhelmus CMChief Operating OfficerSSale−1.21K$75.28−$91.3K−0.7%183.4K after
Mar 6, 2023 (view filing)Mar 24 daysCordova AshleyChief Financial OfficerSSale−1.05K$75.28−$79.4K−1.1%95.0K after
Mar 6, 2023 (view filing)Mar 2-34 daysLeonard Frank XPresident, CNS Cancers USSSale−2.90K$76.95−$223.4K−4.1%67.9K after2 lots
Mar 3, 2023 (view filing)Mar 21 dayLeonard Frank XPresident, CNS Cancers USSSale−4.11K$75.37−$309.6K−6.5%59.0K after2 lots
Mar 2, 2023 (view filing)Mar 11 dayLeonard Frank XPresident, CNS Cancers USSSale−1.68K$76.36−$128.6K−2.6%63.1K after
Mar 2, 2023 (view filing)Mar 11 dayShah PriteshChief Growth OfficerSSale−1.92K$76.36−$146.8K−1.9%100.0K after
Mar 2, 2023 (view filing)Mar 11 dayCordova AshleyChief Financial OfficerSSale−2.20K$76.36−$167.8K−2.2%96.1K after
Mar 2, 2023 (view filing)Mar 11 dayBurke William PatrickChief Human Resources OfficerSSale−755$76.36−$57.7K−1.1%67.0K after
Mar 2, 2023 (view filing)Mar 11 dayGroenhuysen Wilhelmus CMChief Operating OfficerSSale−2.16K$76.36−$165.2K−1.2%184.6K after
Jan 9, 2023 (view filing)Jan 54 daysWeinberg UriChief Science OfficerSSale−8.14K$116.14−$945.8K−15.8%43.3K after4 lots
Jan 9, 2023 (view filing)Jan 54 daysLeonard Frank XPresident, CNS Cancers USSSale−39.5K$112.25−$4.43M−46.1%46.2K after9 lots
Jan 9, 2023 (view filing)Jan 54 daysShah PriteshChief Commercial OfficerSSale−387$108.00−$41.8K−0.5%82.8K after
Jan 9, 2023 (view filing)Jan 54 daysDanziger AsafChief Executive OfficerSSale−212.5K$108.73−$23.1M−94.0%13.6K after10 lots
Oct 17, 2022 (view filing)Oct 134 daysLeonard Frank XPresident, CNS Cancers USSSale−6.75K$76.01−$513.4K−13.4%43.6K after
Oct 7, 2022 (view filing)Oct 61 dayLeonard Frank XPresident, CNS Cancers USSSale−6.75K$84.37−$569.8K−11.8%50.4K after
Sep 30, 2022 (view filing)Sep 291 dayLeonard Frank XPresident, CNS Cancers USSSale−6.75K$77.35−$522.4K−10.6%57.1K after
Sep 26, 2022 (view filing)Sep 224 daysLeonard Frank XPresident, CNS Cancers USSSale−6.75K$77.00−$520.1K−9.6%63.9K after
Sep 19, 2022 (view filing)Sep 154 daysLeonard Frank XChief Development OfficerSSale−12.3K$88.52−$1.09M−14.8%70.6K after2 lots
Sep 13, 2022 (view filing)Sep 85 daysLeonard Frank XChief Development OfficerSSale−6.75K$81.48−$550.3K−8.0%77.4K afterAmended
Sep 7, 2022 (view filing)Sep 61 dayLeonard Frank XChief Development OfficerSSale−1.38K$78.57−$108.7K−1.6%86.0K after
Sep 6, 2022 (view filing)Sep 24 daysBurke William PatrickChief Human Resources OfficerSSale−718$79.04−$56.8K−1.3%55.5K after
Sep 6, 2022 (view filing)Sep 24 daysCordova AshleyChief Financial OfficerSSale−885$79.04−$70.0K−1.2%72.4K after
Sep 6, 2022 (view filing)Sep 24 daysGroenhuysen Wilhelmus CMChief Operating OfficerSSale−296$79.04−$23.4K−0.2%165.0K after
Sep 6, 2022 (view filing)Sep 24 daysShah PriteshChief Commercial OfficerSSale−269$79.04−$21.3K−0.3%83.2K after
Sep 6, 2022 (view filing)Sep 1-25 daysLeonard Frank XChief Development OfficerSSale−14.8K$77.50−$1.15M−14.5%87.4K after13 lots
Aug 4, 2022 (view filing)Aug 31 dayBenaim ElyChief Medical OfficerSSale−5.96K$73.73−$439.3K−17.2%28.7K after2 lots
Aug 3, 2022 (view filing)Aug 21 dayDoyle William FExecutive ChairmanSSale−837$69.66−$58.3K−0.2%551.2K after
Aug 3, 2022 (view filing)Aug 21 dayBenaim ElyChief Medical OfficerSSale−437$69.66−$30.4K−1.2%34.6K after
Aug 3, 2022 (view filing)Aug 21 dayLeonard Frank XChief Development OfficerSSale−414$69.66−$28.8K−0.4%102.2K after
Jun 16, 2022 (view filing)Jun 106 daysLateHilleman Jeryl LDirectorSSale−407$69.61−$28.3K−13.8%2.54K after
May 12, 2022 (view filing)May 10-112 daysBenaim ElyChief Medical OfficerSSale−4.21K$63.17−$265.6K−10.8%34.8K after2 lots
Mar 11, 2022 (view filing)Mar 92 daysShah PriteshChief Commercial OfficerSSale−3.67K$71.19−$261.2K−4.2%83.2K after
Mar 9, 2022 (view filing)Mar 7-82 daysShah PriteshChief Commercial OfficerSSale−7.78K$69.73−$542.1K−8.7%81.9K after2 lots